Health Canada endorsed important safety information on ZOFRAN® (ondansetron hydrochloride dihydrate, ondansetron)

GlaxoSmithKline Inc., in collaboration with Health Canada, would like to notify you of new information regarding the risk of electrocardiographic QT interval prolongation associated with ZOFRAN® (ondansetron). ZOFRAN® (ondansetron) is indicated in adults of all ages for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and in adults ≤65 years of age for the prevention and treatment of post-operative nausea and vomiting. ZOFRAN® (ondansetron) is also indicated in children 4 years of age and older for the prevention of chemotherapy-induced nausea and vomiting. Read more here.